GlassScriptPhysician profile
Jeffery Lynn Schul
NPI 1326025719
$1,123.61
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $996 · 2022: $127.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $211.65 | 2019 | |
| Glaxosmithkline, LLC. | $194.89 | 2019 | |
| Genentech USA, INC. | $177.88 | 2019 | |
| Adma Biomanufacturing LLC | $127.14 | 2022 | |
| Genzyme Corporation | $113.94 | 2019 | |
| Csl Behring | $65.16 | 2019 | |
| Novartis Pharmaceuticals Corporation | $64.30 | 2019 | |
| Optinose US, INC. | $36.00 | 2019 | |
| Circassia INC. | $34.21 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.27 | 2019 | |
| Grifols USA, LLC | $20.31 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.58 | 2019 | |
| Phadia US INC. | $17.40 | 2019 | |
| Pfizer INC. | $15.88 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffery Schul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.